Catalyst Pharmaceuticals publishes corporate presentation on rare disease medicines and USD 615-645 million 2026 revenue guidance

Reuters03-10

Catalyst Pharmaceuticals publishes corporate presentation on rare disease medicines and USD 615-645 million 2026 revenue guidance

Catalyst Pharmaceuticals said it is focused on acquiring, in-licensing, developing and commercializing medicines for rare diseases, and highlighted a buy-and-build growth strategy. The company reported more than USD 700 million in cash and cash equivalents and said it had no funded debt as of 12/31/2025. Catalyst Pharmaceuticals said total net product revenue grew 20% year over year in 2025 to USD 588.8 million. It provided 2026 full-year total product revenue guidance of USD 615 million to USD 645 million, including FYCOMPA guidance of USD 40 million to USD 45 million. Catalyst Pharmaceuticals also said it has more than USD 1 billion of capacity for future transactions and is pursuing near-term accretive acquisitions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618954901?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 23:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618954901","market":"nz","top_or_hot":-1,"title":"Catalyst Pharmaceuticals publishes corporate presentation on rare disease medicines and USD 615-645 million 2026 revenue guidance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Catalyst Pharmaceuticals publishes corporate presentation on rare disease medicines and USD 615-645 million 2026 revenue guidance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Catalyst Pharmaceuticals said it is focused on acquiring, in-licensing, developing and commercializing medicines for rare diseases, and highlighted a buy-and-build growth strategy. The company reported more than USD 700 million in cash and cash equivalents and said it had no funded debt as of 12/31/2025. Catalyst Pharmaceuticals said total net product revenue grew 20% year over year in 2025 to USD 588.8 million. It provided 2026 full-year total product revenue guidance of USD 615 million to USD 645 million, including FYCOMPA guidance of USD 40 million to USD 45 million. Catalyst Pharmaceuticals also said it has more than USD 1 billion of capacity for future transactions and is pursuing near-term accretive acquisitions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Catalyst Pharmaceuticals publishes corporate presentation on rare disease medicines and USD 615-645 million 2026 revenue guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCatalyst Pharmaceuticals publishes corporate presentation on rare disease medicines and USD 615-645 million 2026 revenue guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 23:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Catalyst Pharmaceuticals publishes corporate presentation on rare disease medicines and USD 615-645 million 2026 revenue guidance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Catalyst Pharmaceuticals said it is focused on acquiring, in-licensing, developing and commercializing medicines for rare diseases, and highlighted a buy-and-build growth strategy. The company reported more than USD 700 million in cash and cash equivalents and said it had no funded debt as of 12/31/2025. Catalyst Pharmaceuticals said total net product revenue grew 20% year over year in 2025 to USD 588.8 million. It provided 2026 full-year total product revenue guidance of USD 615 million to USD 645 million, including FYCOMPA guidance of USD 40 million to USD 45 million. Catalyst Pharmaceuticals also said it has more than USD 1 billion of capacity for future transactions and is pursuing near-term accretive acquisitions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0034390439.USD","symbol_name":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL8Yb6Bw:1","article_id":"2618954901","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618954901","pubTimestamp":1773156157,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Catalyst Pharmaceuticals publishes corporate presentation on rare disease medicines and USD 615-645 million 2026 revenue guidance. Catalyst Pharmaceuticals said it is focused on acquiring, in-licensing, developing and commercializing medicines for rare diseases, and highlighted a buy-and-build growth strategy. The company reported more than USD 700 million in cash and cash equivalents and said it had no funded debt as of 12/31/2025. Catalyst Pharmaceuticals said total net product revenue grew 20% year over year in 2025 to USD 588.8 million. It provided 2026 full-year total product revenue guidance of USD 615 million to USD 645 million, including FYCOMPA guidance of USD 40 million to USD 45 million. Catalyst Pharmaceuticals also said it has more than USD 1 billion of capacity for future transactions and is pursuing near-term accretive acquisitions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","CPRX":"Catalyst Pharmaceutical Partners","BK4139":"生物科技"},"translate_title":"Catalyst Pharmaceuticals发布罕见病药物公司演示文稿和2026年6.15-6.45亿美元收入指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPRX":0.9},"content_text":"Catalyst Pharmaceuticals publishes corporate presentation on rare disease medicines and USD 615-645 million 2026 revenue guidance\n    \n\n        Catalyst Pharmaceuticals said it is focused on acquiring, in-licensing, developing and commercializing medicines for rare diseases, and highlighted a buy-and-build growth strategy. The company reported more than USD 700 million in cash and cash equivalents and said it had no funded debt as of 12/31/2025. Catalyst Pharmaceuticals said total net product revenue grew 20% year over year in 2025 to USD 588.8 million. It provided 2026 full-year total product revenue guidance of USD 615 million to USD 645 million, including FYCOMPA guidance of USD 40 million to USD 45 million. Catalyst Pharmaceuticals also said it has more than USD 1 billion of capacity for future transactions and is pursuing near-term accretive acquisitions.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618954901","isCrawlerRequest":true}